PCSK9 inhibition in patients with heart transplantation: A case series.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of clinical lipidology"
DOI: 10.1016/j.jacl.2019.06.010
Abstract: PCSK9 inhibitors are potent low-density lipoprotein cholesterol-lowering medications. There is a lack of data regarding safety and efficacy of PCSK9 inhibitors in cardiac transplant patients. In this case series, we provide data supporting the low-density… read more here.
Keywords: pcsk9 inhibition; pcsk9; case series; pcsk9 inhibitors ... See more keywords
PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).
Sign Up to like & getrecommendations! Published in 2020 at "Metabolism: clinical and experimental"
DOI: 10.1016/j.metabol.2020.154221
Abstract: BACKGROUND Lipoprotein(a) (Lp(a)) is a low-density lipoprotein (LDL) particle containing apolipoprotein(a) (apo(a)) covalently linked to apolipoprotein B-100 (apoB). Statin-treated patients with elevated Lp(a) have an increased risk of atherosclerotic cardiovascular disease (ASCVD). Recent trials show… read more here.
Keywords: patients elevated; statin treated; pcsk9 inhibition; treated patients ... See more keywords
Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.
Sign Up to like & getrecommendations! Published in 2021 at "Pharmacological research"
DOI: 10.1016/j.phrs.2021.105524
Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition, by increasing hepatic low density lipoprotein (LDL) receptor (LDLR) levels, has emerged as a strategy to reduce atherosclerosis by lowering circulating very low density lipoprotein (VLDL)-cholesterol. We hypothesized… read more here.
Keywords: fat activation; inhibition; pcsk9 inhibition; atherosclerosis ... See more keywords
Effects of PCSK9 Inhibition on Coronary Atherosclerosis Regression of Nontarget Lesions after Primary Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Interventional Cardiology"
DOI: 10.1155/2022/4797529
Abstract: Aims To evaluate the regression of coronary atherosclerosis with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition in acute coronary syndrome (ACS) patients following primary percutaneous coronary intervention (PPCI). Methods and Result. We examined 40 nontarget… read more here.
Keywords: coronary atherosclerosis; coronary syndrome; acute coronary; nontarget lesions ... See more keywords
Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0265838
Abstract: Background and aims Familial dysbetalipoproteinemia (FDBL) is a rare inborn lipid disorder characterized by the formation of abnormal triglyceride- and cholesterol-rich lipoproteins (remnant particles). Patients with FDBL have a high risk for atherosclerotic disease. The… read more here.
Keywords: familial dysbetalipoproteinemia; inhibition; cholesterol; pcsk9 inhibition ... See more keywords